Stifel Reiterates Buy Rating on Beam Therapeutics Inc (BEAM), "Like BEAM's Modular Platform and The Growth it Can Bring"
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Buy rating and $120.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
